Is Fermenta Biotech the Best Stock in Its Sector? A Look at the Numbers

Fermenta Biotech CMP Rs 486 (16 Oct 2026). Market cap Rs 1,432 Cr. ROE 17.67%. P/E 24.62x versus Industry P/E 36.42x.

Is Fermenta Biotech the best stock in its sector? The stock trades on the NSE at Rs 486 as of 16 October 2026, within its 52-week range of Rs 248.85 to Rs 582.65. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Fermenta Biotech

Fermenta Biotech Ltd is a Mumbai based company best known for making vitamin D3 and related products. Its products are used in pharmaceuticals, food fortification, animal nutrition and agriculture related applications. At a market capitalisation of Rs 1,432 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.

Is Fermenta Biotech the Best Stock in Its Sector?

Fermenta Biotech makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Fermenta Biotech’s 24.62x P/E is below the 36.42x Industry P/E, Marksans Pharma at 27.32x and Neuland Laboratories at 52.07x, while its 17.67% ROE is lower than Neuland Laboratories at 19.42%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.28 is above Marksans Pharma at 0.11 and Neuland Laboratories at 0.16.

Metric	Fermenta Biotech
CMP (NSE)	Rs 486.50
52-Week High / Low	Rs 582.65 / Rs 248.85
Market Cap	Rs 1,432 Cr
P/E (TTM) vs Industry P/E	24.62x vs 36.42x
P/B	3.52
ROE	17.67%
EPS (TTM)	Rs 19.77
Dividend Yield	0.75%
Debt to Equity	0.28

Compare Fermenta Biotech Against Other Pharmaceuticals Sector Stocks

How Fermenta Biotech Compares Against Its Pharmaceuticals Sector Peers

The table below sets Fermenta Biotech against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Fermenta Biotech	1,432	24.62	17.67%	0.28
Marksans Pharma	14,236	27.32	13.82%	0.11
Neuland Laboratories	25,917	52.07	19.42%	0.16
Peer average (2 companies)	–	39.70	16.62%	0.14

Measured against the peer averages, Fermenta Biotech’s P/E is 38 percent below the 39.70x average, and its ROE is 1.05 percentage points above the 16.62% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Fermenta Biotech Worth Watching in Pharmaceuticals

• Scale: At Rs 1,432 Cr, its market capitalisation is smaller than Marksans Pharma (Rs 14,236 Cr) and Neuland Laboratories (Rs 25,917 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Global demand for vitamin D3 in supplements, fortified foods and animal feed drives its volumes and realisations.
• Key risk: The stock has nearly doubled from its 52-week low, and dependence on a narrow product range exposes earnings to price swings.

Fermenta Biotech Valuation: Is It Justified?

At a P/B ratio of 3.52, the market pays about Rs 3.52 for every rupee of book value, and the EPS (TTM) of Rs 19.77 is the earnings base behind the P/E. The stock trades about 17 percent below its 52-week high and about 95 percent above its 52-week low. The dividend yield of 0.75% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Fermenta Biotech and other Pharmaceuticals sector stocks.

How to Track Fermenta Biotech Before You Invest

Before deciding whether Fermenta Biotech deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.

1. Open the Univest Screener and search for Fermenta Biotech to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Fermenta Biotech gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Fermenta Biotech the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Fermenta Biotech has a 17.67% ROE and trades at 24.62x P/E against a 36.42x Industry P/E. Against the 2 peers compared in this article, its ROE is above the 16.62% peer average and its P/E is below the 39.70x peer average. Its debt to equity ratio of 0.28 is above the 0.14 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Fermenta Biotech?

Ans. Fermenta Biotech was trading at Rs 486.50 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 248.85 to Rs 582.65. That leaves the share price 17 percent short of the 52-week high and 95 percent clear of the 52-week low. Its market capitalisation is Rs 1,432 Cr and its EPS (TTM) is Rs 19.77, which is the earnings figure behind the 24.62x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Fermenta Biotech belong to?

Ans. Fermenta Biotech is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P/E used in this article. The 2 named peers compared here are Marksans Pharma and Neuland Laboratories, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Fermenta Biotech compare to its sector peers on P/E?

Ans. Fermenta Biotech’s P/E of 24.62x is below the 39.70x average of the 2 named peers, with Marksans Pharma at 27.32x and Neuland Laboratories at 52.07x. It also sits below the 36.42x Industry P/E, which is the benchmark for the wider Pharmaceuticals sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 3.52 gives one more view of how the market values its book value.

What is Fermenta Biotech’s return on equity?

Ans. Fermenta Biotech reported a return on equity of 17.67%, which is above the 16.62% average of its named peers, with Marksans Pharma at 13.82% and Neuland Laboratories at 19.42%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.28 against a peer average of 0.14. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Fermenta Biotech based on its sector position?

Ans. Sector position is only one input into an investment decision. Fermenta Biotech has a 17.67% ROE and a 24.62x P/E, which make it worth researching further, and its dividend yield is 0.75%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.